- Trial phase
- Approved
- Time to market
- Already approved and commercialized since February 2021 (US) and June 2021 (EU). Latest label expansion (ages 1-5) approved September 2025.
- Why 4/10
- Evkeeza is already FDA- and EMA-approved and actively marketed; the most recent hard catalyst, the label expansion to children aged 1 to less than 5 years, occurred on September 26, 2025. No new PDUFA or pivotal readout is scheduled in the next ~12 months, and the drug is a small (<~1% of revenue) contributor to Regeneron's $14.3B top line, capping share-price impact potential.
Evkeeza is a first-in-class ANGPTL3 inhibitor approved for an ultra-rare cholesterol disorder (HoFH, ~1,300 US patients). It is already de-risked by FDA approval but contributes only ~$130-150M in annual US sales versus Regeneron's ~$14.3B total revenue. The stock is primarily driven by Dupixent, EYLEA, and the broader pipeline, not this one drug. Watch quarterly Evkeeza US sales for gradual label-expansion uptake, but do not expect binary swings from this asset.
Price Chart
Executive Summary
Evkeeza (evinacumab) is Regeneron's first-in-class ANGPTL3-inhibitor antibody for homozygous familial hypercholesterolemia (HoFH), an ultra-rare genetic condition affecting roughly 1,300 people in the US. FDA-approved since February 2021, its label has progressively expanded to cover all children down to age 1 as of September 2025. The drug is priced at ~$450,000/year list price and generated around $72.1M in US sales in H1 2025. While a meaningful option for a small patient population, Evkeeza is a minor contributor (~1%) to Regeneron's ~$14.3B in annual revenue, and the stock is overwhelmingly driven by larger franchises (Dupixent, EYLEA, Libtayo) and pipeline candidates.
How It Works
Evkeeza is a lab-engineered antibody (a type of protein) that is given as a monthly IV infusion. It works by blocking a protein called ANGPTL3, which normally interferes with the body's ability to break down fats and cholesterol. By blocking ANGPTL3, the drug helps clear "bad" LDL cholesterol from the bloodstream. This is a different mechanism from statins or PCSK9 inhibitors (like Repatha or Leqvio).
Trial Status
Evkeeza gained initial FDA approval in February 2021 for patients aged 12+ with HoFH based on the pivotal Phase 3 ELIPSE HoFH trial, which showed adding evinacumab to standard lipid-lowering therapies reduced LDL-C by ~50% at 24 weeks versus placebo. The label was expanded to children aged 5-11 in 2023 (single-arm open-label trial), and further expanded to children aged 1 to less than 5 in September 2025.
The Two-Sided Case
Upcoming Catalysts
- Quarterly earnings reports showing Evkeeza US sales growth from the label expansion to ages 1-5
- Potential label expansion into broader hypercholesterolemia or severe hypertriglyceridemia (early-stage exploration)
- Ex-US commercialization ramp by Ultragenyx, periodic updates on European/ROW launches and reimbursement
Source Filing
The SecBot filing or press-release report that triggered this drug report:
REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report